Axiogenesis AG is an international leader in the development and commercialization of in vitro models of healthy and diseased cell types and tissue. Axiogenesis' technologies greatly improve the speed and confidence in discovering new therapies, and reduce attrition of failed compounds.
Since 2000, Axiogenesis has been in business to capture the promise of stem cells to revolutionize the fields of drug discovery & development and life sciences research. Axiogenesis develops and commercializes stem cell-derived, in vitro differentiated cardiomyocytes and other cell types, as well as drug development assays and disease models, to help researchers discover cures.
Axiogenesis' flagship offering is the Cor.4U® human cardiomyocyte product, derived from induced pluripotent stem (iPS) cells, which is used in applications for single cell analysis to high-throughput screening (HTS) of pharmaceutical compounds. Cor.4U® cardiomyocytes: Pure. Human.™
Axiogenesis was first-to-market with a pure stem cell-derived cardiomyocyte product, launching Cor.At® murine cardiomyocytes in 2008. Cor.At® cardiomyocytes, along with murine stem cell-derived endothelial cells (Endo.4M) and smooth muscle cells (SMAC.4M), are distributed globally by Sigma Life Sciences. Visit www.sigma.com/cardiac.
Applying Axiogenesis' pure cell types into market-driven solutions, Axiogenesis offers licensing of proprietary disease models, e.g. Hypertrophic Cardiomyopathy (HCM, also known as Cardiac Hypertrophy), for compound screening as well as value-added fee-for-service assays for in vitro toxicology, safety pharmacology and drug discovery.
Contact us to discuss how to use our discoveries to advance yours.